There are various registries for patients with peritoneal metastases (PM) that aid pooling of data and generate evidence that dictates current clinical practice. This manuscript describes the setting up of the Indian HIPEC registry that was set up with a similar goal by a group of Indian surgeons. This is a registry for patients with PM treated with CRS and HIPEC in India. It also acts as a database for storing treatment-related information. Patients with PM from colorectal ovarian, gastric, appendiceal tumors, and other rare peritoneal tumors/metastases from rare tumors are enrolled in the registry. A coordinator updates the disease status of patients on a yearly basis. A private organization maintains the database. A non-disclosure agreement is signed between the company and each surgeon contributing to the registry to maintain confidentiality. For enrolling patients, securing institutional permission depends on the requirement of each institute; patient consent is mandatory. Data entry can be prospective or retrospective. To propose and conduct a study, the approval of a scientific committee linked to the registry is required. The Indian HIPEC registry is a practical database for Indian surgeons. There is no regulatory body that mandates collection and publication of scientific data in India. The onus is on each surgeon to capture valuable information pertaining to these common and rare diseases that could contribute to the existing scientific knowledge and guide the treatment of these patients in the future. The next challenge will be to enter data into the registry.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705519PMC
http://dx.doi.org/10.1007/s13193-017-0693-7DOI Listing

Publication Analysis

Top Keywords

indian hipec
12
hipec registry
12
registry
9
setting indian
8
patients peritoneal
8
indian surgeons
8
patients
7
indian
5
hipec
4
registry registry
4

Similar Publications

Background: The role of enhanced recovery after surgery (ERAS) in cytoreductive surgery and/or Hyperthermic Intraperitoneal Chemotherapy HIPEC) is evolving, with promising results that improve patient outcomes. This consensus exercise was carried out to address and standardize components of the ERAS protocol pertinent to the Indian context.

Method: The modified Delphi method was employed with two rounds of voting.

View Article and Find Full Text PDF
Article Synopsis
  • The manuscript presents findings from the INDEPSO-ISPSM consensus focused on managing colorectal peritoneal metastases (CPM) in India.
  • Researchers used the modified Delphi method to gather opinions from oncologists on key treatment aspects, achieving consensus on 23 out of 29 questions about surgery, chemotherapy, and treatment strategies.
  • The panel strongly supported cytoreductive surgery (CRS) for selected patients and recommended caution with hyperthermic intraperitoneal chemotherapy (HIPEC) and intraperitoneal chemotherapy (IPC) outside clinical trials.
View Article and Find Full Text PDF
Article Synopsis
  • Granulosa cell tumors (GCTs) are common ovarian tumors associated with a good prognosis but a tendency for late recurrences, making treatment difficult.
  • A study evaluated the effects of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) on eight patients with recurrent adult GCTs, showing a median overall survival of 11.5 months post-treatment.
  • The procedure demonstrated acceptable levels of postoperative complications, but more research is needed to confirm its effectiveness as a treatment option for recurrent GCTs.
View Article and Find Full Text PDF

Background: No guidelines exist regarding the management of the uninvolved uterus or adnexa (fallopian tubes and/or ovaries) in patients with peritoneal metastases (PM) from non-gynecologic malignancies. It is unclear whether salpingo-oophorectomy, hysterectomy, or both should be performed when a complete pelvic peritonectomy is otherwise warranted.

Methods: A 25-item electronic survey was sent to 225 surgeons worldwide who routinely perform cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!